The U.S. FTC publishes a report on generic drug entry prior to patent expiration raising issues on patent-shortening settlement agreements

The Federal Trade Commission's recent report, Generic Drug Entry Prior to Patent Expiration (Federal Trade Commission, Generic Drug Entry Prior to Patent Expiration: An FTC Study, July 2002, ("FTC Report")), raises a number of competition issues that merit further discussion and research. This comment will briefly explore the Report’s discussion of patent-shortening settlement agreements. By way of background, some familiarity with the context and complexities of the ANDA/patent infringement litigation process is assumed. In the pharmaceuticals industry, when a generic drug firm (The term "generic firm" can be too simplistic. Upsher-Smith Laboratories is a branded generic firm. It sells pharmaceutical products that include generic versions of branded drugs, but does so under its own

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

  • White & Case (Washington)

Citation

Mark J. Gidley, The U.S. FTC publishes a report on generic drug entry prior to patent expiration raising issues on patent-shortening settlement agreements, 1er juillet 2002, e-Competitions July 2002, Art. N° 37102

Visites 912

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues